NCI-H64細(xì)胞
ATCC Number： CRL-5976?
相關(guān)**： 小細(xì)胞肺癌
數(shù)量： 大量
運輸方式： 凍存運輸
是否是腫瘤細(xì)胞： 1
物種來源： 人
生長狀態(tài)： 漂浮生長
年限： stage E
器官來源： 肺
Designations: NCI-H64 [H64]
Depositors: AF Gazdar, JD Minna
NCI-H64細(xì)胞Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: floating aggregates of round cell clusters
Organism: Homo sapiens
Morphology:
Source: Organ: lung
Tumor Stage: stage E
Disease: carcinoma; small cell lung cancer
Derived from metastatic site: lymph node
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions: NCI-H64細(xì)胞The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. A. Gazdar and Dr. J. Minna and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 699-8056, FAX (214) 688-7233.
Applications: The line was established in May 1977.
DNA Profile (STR): Amelogenin: X
CSF1PO: 10
D13S317: 10
D16S539: 9,12
D5S818: 11
D7S820: 10,12
THO1: 6
TPOX: 8
vWA: 17,18
Cytogenetic Analysis: 3p is normal
Age: 48 years
Gender: female
Ethnicity: Caucasian
Comments: NCI-H64細(xì)胞The line was established in May 1977.
The patient received prior chemotherapy and radiation therapy.
The patient was a smoker.
30 pack years.
Propagation: ATCC complete growth medium: HITES medium supplemented with 20% fetal bovine serum
HITES medium with 5% fetal bovine serum is formulated at the ATCC as follows:
Dulbecco's medium : Ham's F12, 50:50 mix (ATCC 30-2006)
Insulin 0.005 mg/ml
Transferrin 0.01 mg/ml
Sodium selenite 30 nM
Hydrocortisone 10 nM
beta-estradiol 10 nM
HEPES 10 mM
L-glutamine 2 mM (in addition to that in the base medium)
fetal bovine serum 20%
Atmosphere: air, 95%; NCI-H64細(xì)胞carbon dioxide (CO2), 5%
Temperature: 37.0°C
Preservation: Culture medium, 95%; DMSO, 5%
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2006
recommended serum:ATCC 30-2020
References: 23570: . NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996.
